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Here, we review sexually transmitted diseases (STDs) caused by pathogenic bacteria and
vaginal infections which result from an overgrowth of opportunistic bacterial microflora.
First, we describe the STDs, the corresponding pathogens and the antimicrobials used
for their treatment. In addition to the well-known diseases caused by single pathogens
(i.e., syphilis, gonococcal infections, and chlamydiosis), we consider polymicrobial
reproductive tract infections (especially those that are difficult to effectively clinically
manage). Then, we summarize the biochemical mechanisms that lead to antimicrobial
resistance and the most recent data on the emergence of drug resistance in STD
pathogens and bacteria associated with vaginosis. A large amount of research performed
in the last 10–15 years has shed light on the enormous diversity of mechanisms of
resistance developed by bacteria. A detailed understanding of the mechanisms of
antimicrobials action and the emergence of resistance is necessary to modify existing
drugs and to develop new ones directed against new targets.
Keywords: human reproductive system, sexually transmitted diseases, bacterial vaginosis, antimicrobials,
antimicrobial resistance
INTRODUCTION
The infections of human reproductive system include the sexually transmitted diseases (STDs) that
are defined as infections that spread primarily through person-to-person sexual contact, and non-
STDs which are endogenous infections of the genital organs such as bacterial vaginosis (BV). Both
STDs and non-STDs are the major concern for public health systems worldwide.
According to the WHO, each year there are approximately half a billion new cases of STDs
worldwide (WHO, 2014a), of which 105.7 million are chlamydial infections, 106.1 million are
gonorrhea, and 10.6 million are syphilis (WHO, 2013). STDs lead to a decrease in fertility and are
harmful to the offspring. Up to 40% of womenwith untreated gonococcal and chlamydial infections
develop inflammatory diseases of the pelvic organs that lead to infertility in 25% of cases; pregnancy
in women with the untreated early forms of syphilis results in stillbirth in 25% of cases and neonatal
death in 14% (CDC, 2015). Obviously, the timely detection of STDs and adequate antimicrobial
therapy are crucial for the successful treatment and prevention of the spread of the disease.
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STDs are often polymicrobial and are caused not only
by obligate pathogens (Neisseria gonorrhoeae, Chlamydia
trachomatis, Treponema pallidum, and Mycoplasma genitalium)
but also by a variety of opportunistic microorganisms which are
mostly not sexually transmitted and can occur without sexual
relationship. The polymicrobial nature of the reproductive
tract pathologies modifies the clinical pattern of the disease,
aggravates the inflammatory process, and reduces the efficacy
of the determination of their etiologies, which can result in
inadequate treatment (Josey and Schwebke, 2008).
A major worldwide problem is the increase in drug resistance
of pathogens, which makes it difficult to select proper treatments.
In April 2014, the WHO published the report “Antimicrobial
resistance: A global report on epidemiological surveillance”
(WHO, 2014b). The report emphasized the threat of an
increase in the resistance of many pathogens. The greatest
concern in addition to tuberculosis, malaria, and staphylococcal
infection is the emergence of N. gonorrhoeae strains with
reduced susceptibility to third-generation cephalosporins. Thus,
elucidating the etiology of infections and the concurrent
inflammatory processes of the urogenital tract and developing
successful therapies require the detection of the primary
infectious agents in clinical specimens, the simultaneous
identification of a large number of other opportunistic pathogens
and an analysis of their susceptibility to common antimicrobial
drugs.
This review focuses on the characterization of the most
common sexually transmitted bacterial pathogens (excluding
viral, fungal, and parasitic infections) and non-STD infections
which result from an overgrowth of opportunistic bacterial
microflora, and discusses the mechanisms and molecular
determinants of their drug resistance.
BRIEF DESCRIPTION OF THE MOST
COMMON BACTERIAL INFECTION OF THE
HUMAN REPRODUCTIVE SYSTEM AND
THE DRUGS USED TO TREAT THEM
Syphilis
This disease is caused by the sexually transmitted, Gram-
negative, spirochetal bacterium T. pallidum and is characterized
by lesions of the skin, mucous membranes, nervous system,
internal organs, and musculoskeletal system. Syphilis can cause
intrauterine infections of the fetus. The disease can occur in both
symptomatic and latent forms. Despite significant achievements
in the fight against this disease, syphilis remains a challenge
for treatment and public health care due to the variations
in the course of the disease and the diversity of its clinical
manifestations. Syphilis is treated with benzathine penicillin
G, tetracycline and its derivative doxycycline, macrolides (e.g.,
erythromycin and azithromycin), and cephalosporins (e.g., the
third generation drug ceftriaxone). The main drug of choice
for syphilis treatment in the 2015 CDC recommendations is
benzathine penicillin G (Workowski and Bolan, 2015). Patients
allergic to penicillin are treated with the other antibiotics
mentioned above. In clinical trials, some antibiotics (e.g.,
azithromycin) proved to be more effective than penicillin G for
the treatment of early syphilis (Bai et al., 2008).
Gonococcal Infection
Gonorrhea is one of the most common STDs and is caused by the
Gram-negative diplococci N. gonorrhoeae. Health complications
resulting from the gonococcus disease occur mainly in women
and are largely attributed to the predominately asymptomatic
nature of lower genital tract, i.e., cervical, infection. Untreated,
subclinical infection of the cervix can lead to upper genital
tract involvement (e.g., salpingitis) and, potentially, to infertility.
The infection primarily affects the genitals, including the
cylindrical and glandular epithelium. Although gonococcal
vaginitis develops in female children in which menarche has not
yet occurred, keratinization occurring with menarche prevents
gonococcal vaginitis in the adult female (Edwards and Butler,
2011).
Gonococcal infection is usually treated with ciprofloxacin,
ofloxacin, spectinomycin, and β-lactam antibiotics; currently,
the most effective recommended drugs are ceftriaxone and
azithromycin (Workowski and Bolan, 2015). The widespread
occurrence of penicillin-resistant gonorrhea has led to a decrease
in the use of first and second generation β-lactams, protected
penicillins (clavulanate-potentiated amoxicillin or ticarcillin-
clavulanate), and cephalosporins in clinical practice. Ceftriaxone
belonging to cephalosporin drugs, that are more resistant to
β-lactamases, remains widely used.
Spectinomycin, from the aminocyclitol class of drugs closely
related to the aminoglycosides, since 1960s was used for specific
treatment of gonorrhea. It was useful in an alternative therapy
for gonorrhea resistant to antibiotics of the other groups or in
patients allergic to β-lactams. After 10–20 years of treatment,
spectinomycin-resistant gonococcal strains were reported in
Netherlands, South Korea, United Kingdom, and USA (Unemo
and Shafer, 2014). There is a consistent trend of increasing
resistance of gonococci to spectinomycin in Russia (up to 15%
in 2010) (Kubanova et al., 2010, 2014). Spectinomycin is not used
now as a first-line drug for gonorrhea therapy in many countries.
Chlamydiosis
The infection is caused by the Gram-negative intracellular
bacterium C. trachomatis. There are 15 identified serovars of C.
trachomatis. Serotypes Ab, B, Ba, and C are pathogens that cause
trachoma, serovars D, E, F, G, H, I, J, and K cause urogenital
chlamydiosis, urethritis, prostatitis, vaginitis, and chlamydial
cervicitis, and serovars L1, L2, and L3 cause lymphogranuloma
venereum and genital ulcers (Workowski and Bolan, 2015). The
socio-economic significance of urogenital chlamydial infection is
due not only to the high rate of disease but also to a significant
percentage of complications, especially the development of
secondary infertility in men and women (Vasilevsky et al., 2014).
The drugs of choice for the treatment of chlamydial infections
are tetracyclines (doxycycline) and macrolides (josamycin and
azithromycin); alternatively, fluoroquinolones (levofloxacin and
ofloxacin) can be used (Workowski and Bolan, 2015). Despite
the availability of a whole range of drugs against chlamydia, its
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treatment is not always successful due to the presence of co-
infections with the causative agent of urogenital ureaplasmosis
(Ureaplasma urealyticum). Thus, adequate therapy requires the
accurate identification of additional microorganisms associated
with the chlamydia infection and the simultaneous treatment of
opportunistic infections.
Mycoplasmosis and Ureaplasmosis
The diseases are caused by opportunistic microorganisms of the
genusMycoplasma (M. genitalium andMycoplasma hominis) and
Ureaplasma. The latter is classified in a separate genus due to
its ability to break down urea. Researchers have identified two
species of Ureaplasma (U. parvum and U. urealyticum) that are
further classified into 14 serovars. Mycoplasma and ureaplasma
are detected in more than 40% of patients with inflammatory
diseases of the urogenital system; three species have the highest
clinical significance (M. genitalium, U. urealyticum, and M.
hominis). Mycoplasma and ureaplasma can cause urethritis
in both sexes and probably cervicitis, cystitis, and pregnancy
complications including post-partum period and post-abortion
complications (Larsen and Hwang, 2010). The drugs of choice
for the treatment of infections are macrolides (azithromycin
and josamycin) and tetracyclines (doxycycline). Alternative
medications are fluoroquinolones (levofloxacin and ofloxacin)
(Workowski and Bolan, 2015).
Bacterial Vaginosis (BV)
BV is an infectious non-inflammatory disease of a polymicrobial
nature that is predominantly detected in women of reproductive
age. The disease is not immediately life-threatening, but it is a
risk factor for pregnancy complications and pelvic inflammatory
diseases. Moreover, BV is associated with increased risk for
acquiring sexually transmitted infections (Martin, 2012). For
example, BV can increase a woman’s risk of acquiring N.
gonorrhoeae (gonococcal infection hazard ratio: 1.7; 95% CI: 1.1–
2.6), C. trachomatis (chlamydial infection odds ratio: 3.4; 95% CI:
1.5–7.8), and Trichomonas (trichomonal genital infection hazard
ratio: 1.8; 95% CI: 1.3–2.4) (Margolis and Fredricks, 2015).
BV occurs as the result of a drastic imbalance in the normal
vaginal microflora rather than as an invasion of a foreign
pathogen. In this case, the normal protective lactobacilli are
replaced by high quantities of anaerobes (Turovskiy et al., 2012;
Margolis and Fredricks, 2015). Among the most commonly
detected causative agents of the disease are the microaerophilic
bacteria Gardnerella vaginalis, obligate anaerobic Gram-positive
bacteria (Mobiluncus spp. and Peptostreptococcus spp.), and the
facultative anaerobic bacteria Atopobium vaginae. Additionally,
the obligate anaerobic Gram-negative bacteria Prevotella spp.,
Bacteroides spp., and Fusobacterium spp. are sometimes present
in clinical samples (Verhelst et al., 2004; Menard, 2011). The list
of bacteria that have been shown to be associated with vaginosis is
constantly widening (i.e.,Dialiester, Prevotella, andMegasphaera)
(Margolis and Fredricks, 2015).
G. vaginalis bacteria are commonly detected at moderately
high concentrations in BV-positive women but their presence
alone is not specific for BV (Kalra et al., 2007). The frequent
detection of genital mycoplasmas together with anaerobic
microflora is due to the ability of G. vaginalis to secrete
succinic acid, which is used by other microorganisms.
In turn, ureaplasma and mycoplasma, which actively
consume oxygen during their metabolism, stimulate the
proliferation of anaerobic bacteria (Africa et al., 2014).
Agents active against G. vaginalis include metronidazole
and clindamycin.
The proportion of A. vaginae (another causative agent of
vaginitis) ranges from 50 to 95%. This Gram-positive anaerobic
bacillus from theCoriobacteriaceae family produces organic acids
and can be found together with G. vaginalis within the layer
of microorganisms on the surface of the vaginal mucosa in
bacterial vaginosis patients (Verhelst et al., 2004). The dominant
growth of A. vaginae is also treated with metronidazole and
clindamycin.
Mobiluncus is a motile anaerobic microorganism belonging
to the family Actinomycetaceae. Two species of the genus
Mobiluncus are usually found in the human genitourinary tract
(M. curtisii and M. mulieris). Both bacteria are susceptible
to β-lactam antibiotics, glycopeptide drugs, clindamycin,
chloramphenicol, and rifampicin and are primarily resistant
to metronidazole (Spiegel, 1987). Currently, infections caused
by Mobiluncus spp. are commonly treated with clindamycin
(Verstraelen and Verhelst, 2009).
Bacteroides fragilis is a Gram-negative anaerobic bacterium
that is a constituent of the normal microflora of the vagina and
vulva. B. fragilis may cause pyelonephritis, cystitis, urethritis,
prostatitis, and other infectious diseases of the genitourinary
system in both sexes. The main drug for the treatment of
infections caused by B. fragilis is metronidazole (Löfmark
et al., 2010); alternative treatments include β-lactam antibiotics
in combination with β-lactamase inhibitors, clindamycin and
chloramphenicol.
Taking into account the leading role of obligate anaerobic
bacteria in BV, the drugs of choice for BV treatment are those with
anti-anaerobic activity (e.g., clindamycin and 5-nitroimidazole
derivatives). Notably, effective BV treatment must be based on
a differential diagnosis with other urogenital diseases caused
by pathogens (N. gonorrhoeae, C. trachomatis, Trichomonas
vaginalis, and M. genitalium) (Menard, 2011; Workowski and
Bolan, 2015).
DRUG RESISTANCE OF STD PATHOGENS
The continuously increasing resistance of STD pathogens to
antimicrobial agents is a worldwide problem. Antibiotics that
have lost their effectiveness are replaced by new drugs, but
new strains appear with new determinants of resistance; this
issue applies to all classes of drugs. The increase in the
resistance and diversity of the drugs used in clinical practice
leads to the emergence of bacteria with multidrug resistance
(MDR). Some strains with MDR have the ability to spread
rapidly (so-called high-risk clones). Some pathogens acquire
simultaneous resistance to most drugs developed for their
treatment (extensively drug-resistant pathogens) or even to
all drugs (pandrug resistance) (Unemo and Nicholas, 2012;
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Rossolini et al., 2014). Currently, multidrug-resistant isolates
have been identified for both Gram-positive and Gram-negative
species, including N. gonorrhoeae.
T. pallidum
Although diagnostic tests for syphilis and antibiotic therapy are
now available, the disease remains endemic in many developing
countries. Widespread syphilis epidemics occurred in Russia in
the 1990s (Stamm, 2010) and more recently in China (Tucker
and Cohen, 2011). A recent increase in syphilis rates in women
and infants in the USA has also been described (CDC, 2015).
Although penicillins have been used for the treatment of
syphilis for 70 years, no natural penicillin-resistant forms have
been found. To date, no clinically proven cases of treatment
failure using penicillin-related drugs have been described in
patients with syphilis. However, the possibility of the emergence
of acquired resistance is still discussable (Stamm, 2010). Recent
analysis of T. pallidum resistance to antibiotics in the Russian
Federation revealed no resistance to β-lactam antibiotics.
Specifically, no meaningful mutations were found in the tp47 and
tromp genes encoding the targets of β-lactams (Kubanova et al.,
2013).
Currently, there is no documented resistance of T. pallidum to
the tetracyclines. Clinically significant resistance of T. pallidum
to macrolides (a second-line alternative to penicillin) has been
demonstrated by many authors, and macrolide-resistant strains
are now prevalent in several developed countries (Stamm, 2010).
Clinical cases ofT. pallidum resistance tomacrolides (particularly
erythromycin; Stamm and Bergen, 2000), azithromycin (Katz
and Klausner, 2008; Stamm, 2010), clarithromycin (Stamm,
2010), and spiramycin (Mateˇjková et al., 2009) have been
reported. There was a report concerning treatment failure with
clindamycin but these data were not confirmed and T. pallidum
appeared to have intrinsic resistance to this drug (Stamm, 2010).
The first strain resistant to erythromycin and azithromycin
was isolated in 1977 (Street strain 14) (Stamm, 2012). Sequencing
of the T. pallidum genome has shown that it lacks the genetic
elements responsible for horizontal gene transfer (plasmids
and transposons); thus, it was concluded that the resistance
to macrolides in Street strain 14 emerged endogenously by a
spontaneous chromosomal mutation in the 23S rRNA gene. The
mutations responsible for macrolide resistance were shown to
be A2058G and A2059G (23S rRNA). Mutation A2058G was
reported in several areas of the USA, Canada, Europe, and China
(Stamm, 2012), whereas the replacement of A2059G was less
common but was not geographically isolated (Mateˇjková et al.,
2009; Cruz et al., 2013). There were reports concerning patients
with T. pallidum bearing the A2059G mutation in the Czech
Republic (Mateˇjková et al., 2009), Columbia (Cruz et al., 2013),
and the UK (Tipple et al., 2011). The proportion of isolates
resistant to macrolides has been growing, indicating a need for
further drug development and surveillance for resistance in T.
pallidum (Tipple et al., 2011).
N. gonorrhoeae
The pathogen N. gonorrhoeae is characterized by an
extraordinary ability to develop resistance to clinically used
antimicrobial drugs within 10–20 years (Unemo and Nicholas,
2012). N. gonorrhoeae is able to quickly accumulate mutations
and acquire resistance to drugs, including multiple drug
resistance. There are now strains of N. gonorrhoeae that
are resistant to all major drugs used to treat gonorrhea,
including β-lactams, fluoroquinolones, macrolides, tetracyclines,
spectinomycin, cephalosporins, and azithromycin. The spread
of super-resistant forms of the gonorrhea pathogen is a major
concern and requires the strengthening of control on a global
scale (WHO, 2014b). Given the rate of increase ofN. gonorrhoeae
resistance to other drugs, some cases of gonorrhea may become
incurable by 2021 because no vaccines or new drugs are being
developed (Unemo, 2015). Unemo and his coworkers in Sweden
and the WHO report have repeatedly stressed that the situation
with drug-resistant gonorrhea can spiral out of control; thus, it
is extremely urgent to develop rapid genetic analysis methods to
monitor the resistance patterns of the pathogen worldwide and
to apply these data to the treatment of patients (Unemo et al.,
2014; WHO, 2014b).
Gonococci use most of the known mechanisms to acquire
resistance: the inactivation of the antibiotic, alteration of
the drug binding sites, reduction of membrane permeability,
and increased drug eﬄux (Figure 1). The bacteria acquire
these new characteristics via chromosomal mutations,
plasmids carrying the determinants of resistance (i.e., TEM-
1, TEM-135-encoding plasmids for resistance to penicillins,
TetM-encoding plasmids for tetracycline resistance), and
horizontal gene transfer from other species, especially
from other species of Neisseria. Mutations altering the
membrane permeability and increasing the activity of the
eﬄux pumps are particularly efficient in the emergence of in N.
gonorrhoeae because both mechanisms affect a wide variety of
drugs.
When the penicillin treatment regimen was initiated in the
1940s, this drug was highly effective against gonococci. However,
within the next 10–15 years a gradual decrease in penicillin
susceptibility was observed; this decrease was mainly due to
the sequential accumulation of chromosomal mutations in the
bacteria. As the result, strains with MIC for penicillin as high as
4.0 mg/L were formed. Over the next few years, the same process
was repeated with erythromycin, tetracycline, and azithromycin
(Unemo and Shafer, 2014).
There are several mechanisms that explain the resistance ofN.
gonorrhoeae to β-lactam antibiotics. First, the bacteria produce
TEM β-lactamases using a plasmid gene (N. gonorrhoeae does not
produce chromosomally-encoded beta-lactamases). Because the
gonococcal β-lactamase encoded by the plasmid gene blaTEM−1 is
not able to destroy cephalosporins, these antibiotics have taken a
leading role in the treatment of gonorrhea (Klausner and Kerndt,
2013). Mutations that decrease the affinity of the corresponding
penicillin-binding proteins PBP1 and PBP2 to penicillins have
been identified in the chromosomal genes ponA and penA. The
main mutation in the ponA gene leading to the development of
resistant phenotype is L421P (Lindberg et al., 2007; Endimiani
et al., 2014), whereas an insertion in the penA gene leads to
the appearance of D345 (Lindberg et al., 2007; Jeverica et al.,
2014). The insertion of an extra codon for D345 in the wild-type
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FIGURE 1 | Resistance determinans in N. gonorrhoeae for widely used antimicrobial drugs (a general scheme). Resistance to β-lactam antibiotics
(penicillins) appears due to the presence of blaTEM−1plasmid, encoding β-lactamase, and mutations in penicillin-binding proteins PBP1 and PBP2 (penA and ponA
genes); cephalosporins, mutations in plasmid genes encoding β-lactamase and penA gene involving appearance of mosaic penA alleles with up to 70 amino acid
alterations; fluoroquinolones, mutations in gyrA and parC genes encoding DNA gyrase and topoisomerase; tetracyclines, the presence of tetM-encoding plasmids
and mutations in rpsJ gene encoding S10 ribosomal protein (ribosome 30S subunit); macrolides, mutations in 23S RNA genes encoding peptidyltransferases,
rRNA-methylases; spectinomycin, mutations in rpsE gene encoding S5 ribosomal protein (23S rRNA); various classes of drugs, structural changes in major outer
membrane porin protein (PorB) resulting in reducing of membrane permeability; and also mutations in efflux pump genes, particularly, in mtrR genes in the promoter or
coding region, causing increased efflux.
penA gene results in a four-fold reduction in the susceptibility of
gonococci to penicillin (Spratt, 1988).
In addition to the various mechanisms of penicillin resistance
of N. gonorrhoeae described above, a mutation in the pilQ2 gene
(E666K) was found to increase resistance to penicillin in vitro.
E666K works in combination with mutations in the penA, mtrR,
and penB genes (Zhao et al., 2005; Helm et al., 2007). Because
mutations in the pilQ2 gene disrupt the formation of pili, which
are required for the pathogenicity of gonococci, it is unlikely that
similar genotypes could be found in clinical specimens.
During the past few years, the rate of gonococcal strains
resistant to penicillin in the Russian Federation has varied
between 9.6 and 13.2% (Kubanova A. et al., 2014). Globally,
the proportion of resistant N. gonorrhoeae strains has widely
varied: 81% in China, 85% in Switzerland, 79% in Hungary,
27% in Poland, and 9.9% in Belarus in 2009 (Unemo, 2015).
At present, strains have been isolated that exhibit resistance
to extended-spectrum cephalosporins (including ceftriaxone),
which are the last drugs available for gonorrhea monotherapy.
The detections of isolates with decreased susceptibility to
cephalosporins (especially ceftriaxone) has been reported from
all over the world (Unemo and Shafer, 2014). On average, the
proportion of strains with reduced susceptibility to cefixime
(MIC> 0.125mg/L) in the European Union is approximately 8%
(Unemo, 2015).
The reduced susceptibility mechanism is dependent on the
mosaic organization of the penA gene, which may result
from genetic recombination between the N. gonorrhoeae, N.
cinera, and N. perflava species (Ohnishi et al., 2011). The
resistance of N. gonorrhoeae (especially broad drug resistance to
penicillins and cephalosporins) is associated with the emergence
of mosaic alleles of penA and non-mosaic alleles carrying the
A501 mutation. Mosaic alleles contain up to 70 amino acid
substitutions compared to the wild-type protein. The mutations
Frontiers in Microbiology | www.frontiersin.org 5 May 2016 | Volume 7 | Article 747
Shaskolskiy et al. Drug Resistance in Reproductive Tract Bacteria
G545S, I312M, and V316T were found in strains resistant
to broad spectrum cephalosporins. Their resistance can be
explained by modification of the β-lactam binding site (Unemo
et al., 2012; Lewis et al., 2013; Golparian et al., 2014). Notably,
the introduction of these three mutations in the wild-type PBP2
has almost no effect on the resistance of the pathogen N.
gonorrhoeae; these mutations enhance pathogen resistance only
in the presence of other mosaic alleles in the penA gene. It is
possible that this effect is due to epistasis (the suppression of a
non-allelic gene) (Tomberg et al., 2010).
Reduced susceptibility of the gonorrhea pathogen to
ceftriaxone is also associated with mutations of codon 501 in
non-mosaic alleles of penA (most often A501V but sometimes
A501T). The A501 mutation is assumed to be specific for N.
gonorrhoeae because it is not found among other Neisseria; this
mutation possibly appeared spontaneously in gonococci under
selective antibiotic pressure and was not acquired from another
species (Unemo et al., 2012). A detailed study of mutations
in the penA gene of N. gonorrhoeae leading to its resistance
to third generation cephalosporins (cefixime and ceftriaxone)
was published by Kubanova et al. (Kubanova et al., 2014).
Increased resistance to ceftriaxone was observed in the presence
of mutations at positions 346, 505, 511, 517, 543, 567, 575, and
576 of PBP2. The replacement of glycine with serine at position
543 results in a manifold increase in resistance to ceftriaxone.
The first highly resistant strain to ceftriaxone (H041; NG-
MAST ST4220) was a sporadic case in Japan. Another strain
with a similar level of resistance (F89; NG-MAST ST1407; and
MLST ST7363) was first described in France and now has spread
throughout the world. These strains cause unsuccessful attempts
of patient treatment with cefixime and ceftriaxone (Unemo and
Nicholas, 2012; Morita-Ishihara et al., 2014). The N. gonorrhoeae
H041 and F89 strains are highly resistant to third generation
cephalosporins with a minimal inhibitory concentration (MIC)
of 2–4mg/L. An investigation of the N. gonorrhoeae strain H041
revealed 13 additional amino acid substitutions in a mosaic allele
X penA compared to the mosaic penA gene from the strain
with intermediate-level cephalosporin resistance (specifically,
the mutations A311V and T316S located near the β-lactam-
binding pocket close to the active-site nucleophile Ser310 and the
mutation Thr483 that may interact with the carboxylate of the β-
lactam antibiotic) (Tomberg et al., 2013). Two cases of extended-
spectrum cephalosporin-resistant N. gonorrhoeae were recently
isolated from patients in South Africa. These strains were shown
to belong to a multidrug-resistant gonococcal clone (MLST
ST1901) that was associated with several cefixime treatment
failures in Europe and North America (Lewis et al., 2013).
The resistance ofN. gonorrhoeae to macrolides (azithromycin)
is caused by the presence of the erm (erythromycin ribosome
methylation) and mef (associated with the active eﬄux of
antibiotics) genes. The substitution C2611T (Ng et al., 2002) in
the 23S rRNA gene (the rrl gene) leads to the emergence of strains
with moderate resistance, whereas A2059G (Katz et al., 2012;
Unemo et al., 2014) leads to the emergence of highly resistant
strains. In addition to the nucleotide substitutions themselves,
resistance depends on the number of mutant alleles. Unemo
et al. (2014) demonstrated that the presence of the C2611T
substitution in all four alleles resulted in a high level of resistance,
whereas strains with one mutant allele did not differ from the
wild type.
N. gonorrhoeae becomes resistant to tetracycline either of
the expression of a plasmid-encoded TetM protein or by a
combination of three gene mutations: (i) the mtrR mutation,
which results in overexpression of an nonspecific eﬄux pump
(MtrC-MtrD-MtrE) that promotes the eﬄux of a range of
hydrophobic agents and detergents; (ii) the penB determinant,
which is a mutated porin IB that decreases the influx of
tetracycline into the cell, and (iii) and mutations in the rpsJ gene
that result in the amino acid substitution V57M in the ribosomal
protein S10 (Nguyen et al., 2014). Although the combination of
these mutations does not confer a level of tetracycline resistance
as high as that observed with tetracycline-specific eﬄux pumps or
the TetM determinant, the mtrR-penB-rpsJ1 gene triad is highly
effective and provides levels of resistance above those clinically
achievable at the site of infection. In the same time, the rpsJ
allele acts independently of other resistance factors and increases
the MIC of tetracycline between three- and four-fold (Hu et al.,
2005).
There are several determinants of N. gonorrhoeae resistance
to spectinomycin that binds to the 30S ribosomal subunit and
inhibits translation during elongation by blocking the EF-G-
catalyzed translocation of peptidyl-tRNA from the A site to the
P site. One of these determinants affects the segment formation
of the spectinomycin binding site (rrs gene) by introducing
one mutation in the 16S rRNA (G1064C, G1058C, or C1192U)
(Galimand et al., 2000). A high-level spectinomycin-resistant
(MIC > 1mg/L) N. gonorrhoeae strain was isolated in Norway.
The resistance determinant was a deletion of codon 27 (valine)
and a K28E alteration in the ribosomal protein S5 (Unemo et al.,
2013). Mutation T24P in the rpsE gene leading to spectinomycin
resistance has also been described (Ilina et al., 2013). Generally,
there are few examples of MIC-verified stains of N. gonorrhoeae
with high-level resistance to spectinomycin (Kirkcaldy et al.,
2013; Unemo, 2015). However, in Russia the proportion of
spectinomycin-resistant isolates increased from 0.9 to 11.6% in
a short period between 2009 and 2012 (Kubanova A. et al., 2014).
At the end of 80’s, since the introduction of quinolones
(fluoroquinolones) for the primary treatment of uncomplicated
gonorrhea, most of the isolates of gonococci were found to be
extremely susceptible to fluoroquinolones. Since the importance
of antimicrobial susceptibility studies was understood, data
concerning fluoroquinolone-resistant N. gonorrhoeae strains
became available from all parts of the world (Knapp et al.,
1997). In these studies, it was evident that the resistance toward
fluoroquinolones, which is chromosomally mediated, develops
in an incremental manner. The initial isolates which were less
susceptible toward ciprofloxacin were found to have MIC values
of 0.06mg/L, which gradually increased to 1mg/L (such strains
being referred to as intermediate resistant) and later to as high
as 16 mg/L (classified as resistant isolates). Strains with MIC >
4mg/L were considered as high level resistance strains.
The main mechanism of resistance to fluoroquinolones is
the decrease in the affinity of the drug for the DNA-enzyme
complex. This decrease is caused by mutations in the gyrA,
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gyrB, parC, and parE genes in the topoisomerase polypeptide
chains that form the “quinolone pocket.” The resistance of N.
gonorrhoeae to fluoroquinolones is associated with mutations
S91F and D95N/G in gyrA gene and D86N, S88P, and E91K
in parC gene (Vereshchagin et al., 2004). Mutations in parC at
positions 87, 104, and 131 have also been described. Isolates with
high level resistance may carry several mutations in the gyrA
and parC genes (Vereshchagin et al., 2004; Pottumarthy et al.,
2006). The more recent (fourth generation) fluoquinolones are
more active against strains with altered ParC, but are less effective
against GyrA mutants, thus, these compounds will in theory, be
active against some, but not all, ciprofloxacin-resistant gonococci
(Patel et al., 2011).
Resistance ofN. gonorrhoeae to different antibiotics also arises
as the result of modifications in the protein that transports
antibiotics across the outer membrane (the porin PorB). In N.
gonorrhoeae, porins are encoded by the porB gene and have a
molecular mass ranging from 34 to 38 kDa in different strains
(Zeth et al., 2013). Protein molecules form three-dimensional
structures that puncture the outer membrane. Analysis of the
penicillin- and tetracycline-resistant strains of N. gonorrhoeae
revealed the G120D, A121D, and G121K mutations in the porin
protein. Further studies demonstrated that these mutations were
important for the diffusion of antibiotics (Olesky et al., 2006).
In the same work, Olesky et al. described the G120K, G120D,
and A121D mutations in the gene encoding N. gonorrhoeae
porins. These mutations in the porin genes are widely spread
and have been reported in Russia (Ilina et al., 2008), Switzerland
(Endimiani et al., 2014), and Canada (Thakur et al., 2014).
Notably, mutations in the porB gene do not increase the
resistance of N. gonorrhoeae to β-lactams in the absence of
mutations in the mtrR gene (a transcriptional repressor of the
mtrCDE operon). Thus, the increase in resistance is caused by
combined effort of the MtrC-MtrD-MtrE pump and PorB1b,
which decreases the concentration of the antibiotic in the
periplasm of the microorganism (Veal et al., 2002; Olesky et al.,
2006).
Four eﬄux pump systems (MtrCDE, MacAB, NorM, and
FarAB) have been found in gonococci belonging the RND,
ABC, MATE, and MFS superfamilies (Alvarez-Ortega et al.,
2013; Sun et al., 2014; Li et al., 2015; Sharkey et al., 2016),
respectively (Figure 2). The most studied eﬄux pump from N.
gonorrhoeae (MtrC-MtrD-MtrE from the RND superfamily) is
responsible for the eﬄux of β-lactam antibiotics, macrolides,
rifampin, detergents, fatty acids, steroid hormones, and cationic
peptides (Veal et al., 2002). The eﬄux system involves a linker
(MFP), a transporter, and a protein that forms a channel across
the outer membrane (OMP protein). Inactivation of the MtrCDE
pump in clinical isolates displaying high levels of MDR leads to
significant decrease in the resistance to azithromycin, penicillin,
and tetracycline (Golparian et al., 2014). Mutations inmtrR gene
lead to the emergence of penicillin-resistant strains by increasing
the expression of the MtrC-MtrD-MtrE eﬄux pump. Some of
these mutations are located in the coding region and cause the
amino acid substitutions A39T, R44H, G45D, and L47P (Ilina
et al., 2008; Endimiani et al., 2014); others affect the promoter
region (e.g., the insertions insTT at position −10 and deletion
A
B
FIGURE 2 | Schematic representation of efflux systems found in N.
gonorrhoeae. (A) MtrCDE, ternary efflux system crossing inner and outer
membranes (RND superfamily). OMP, outer membrane channel protein; MFP,
membrane fusion protein. Specific mutations in the promoter and/or coding
sequence of mtrR—transcriptional repressor of the mtrCDE operon increase
expression of the MtrCDE pump resulting in the increase in drug resistance,
particularly, to ceftriaxone (mtrR mutations can also activate the penB
resistance determinant). (B) Single-component transporters (ABC, MFS, MATE
superfamilies). NorM is responsible for the efflux of fluoroquinolones,
aminoglycosides, tetracyclines, FarAB—efflux of hydrophobic substances
including macrolides. Overexpression of MacAB pump increases, mainly, MIC
of macrolides. For the removal of antimicrobials ABC transporters use ATP as
an energy source, other transporters employ an electrochemical gradient of
cations, usually, protons.
delA at position −35) (Lindberg et al., 2007; Ilina et al., 2008;
Endimiani et al., 2014). The most common mutations are the
deletion delA in the promoter region and the substitution G45D
in the coding region of the gene. Other rarer mutations also
exist, such as the insertion of 153 bp between the mtrR/mtrC
promoter and themtrC gene. The resistance of N. gonorrhoeae to
fluoroquinolones is greatly increased by the G45D or −35 delA
mutations (Zarantonelli et al., 1999).
The macA and macB genes for MacAB system are organized
as an operon. A SNP in the promoter region increases the
transcription of macAB and results in an increased resistance
to macrolides (Rouquette-Loughlin et al., 2005). The Na/cation
antiporter NorM belonging to MATE superfamily in N.
gonorrhoeae removes fluoroquinolones, aminoglycosides, and
cationic dyes. Inactivation of NorM results in an to eight-
fold decrease in the MIC for tetracycline (Golparian et al.,
2014). Mutation of the promoter region of the norM gene has
been shown to reduce susceptibility to the fluoroquinolones
ciprofloxacin and norfloxacin (Rouquette-Loughlin et al., 2003).
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In addition, the mef -encoded eﬄux pump protein, which is
located on a conjugative transposon has been also found in
N. gonorrhoeae strains. The protein exports macrolides out
of the cell, thus, its overexpression results in resistance to
macrolides (Luna et al., 2000). There is a synergistic interaction
between the change in membrane permeability and the activity
of eﬄux pumps. For example, simultaneous mutations in the
porin protein and eﬄux pump from the RND superfamily in N.
gonorrhoeae result in a significant increase in pathogen resistance
to penicillin and ceftriaxone (Shafer and Folster, 2006).
As mentioned above, a multidrug-resistant strain from South
Africa (Lewis et al., 2013) was resistant to cefixime, ciprofloxacin,
penicillin, and tetracycline, exhibited intermediate resistance
to azithromycin and was susceptible to ceftriaxone and the
aminoglycosides, gentamicin and spectinomycin. The pathogen
carried determinants of resistance for several antibiotics:
mutations in the promoter region of mtrR gene (deletion A)
resulting in overexpression of theMtrC-MtrD-MtrE eﬄux pump;
G101K and A102N in porB1b encoding loop 3 of PorB1b, which
decreases the influx of antibacterial drugs into the cell; mutation
L421P in the ponA1 gene that encodes the second penicillin target
PBP1, thereby reducing the penicillin acylation of PBP1; and
mosaic allele penA, type XXXIV, encoding the penicillin-binding
protein PBP2.
Thus, N. gonorrhoeae has developed resistance to all
antimicrobials introduced for first-line therapy during the
last 70–80 years, and, probably, for more sustainable future
treatment. To overcome this problem it is necessary to focus
not only on derivatives of previously developed antimicrobials
but also on the development and investigation of new targets,
compounds, and approaches for treatment. As an example of
such developments, the topoisomerase II inhibitor ETX0914
(also known as AZD0914) belonging to spiropyrimidinetriones
was introduced as an antimicrobial compound. The mechanism
of its action differs from the mechanisms of all previously
and currently used drugs. The ETX0914 pharmacodynamic
properties, antimicrobial susceptibility and genetic resistance
mechanisms are now extensively studied for the future
application as oral monotherapy or in dual combinations with
ciprofloxacin, azithromycin, or ceftriaxon (Foerster et al., 2015).
C. trachomatis
Information concerning the occurrence and clinical importance
of C. trachomatis resistance to antibiotics is scarce and
contradictory (Kohlhoff and Hammerschlag, 2015). Cases of
multidrug resistance have been reported in C. trachomatis
(Shkarupeta et al., 2007; Sandoz and Rockey, 2010). For example,
failure of treatment with macrolides and doxycycline was
reported in patients with chlamydial infection. Clinically isolated
strains resistant to doxycycline, azithromycin, josamycin,
spiramycin, and ofloxacin were reported, as were multidrug-
resistant strains. Although certain molecular markers associated
with resistance to macrolides and fluoroquinolones have been
described, no functional relationship between the presence
of these markers and the efficacy of antibiotic therapy for
Chlamydia has been established. No mutations were found
in the gyrA, gyrB, parC, and parE genes (resistance to
fluoroquinolones) and in the 23S rRNA V-domain, which
contains macrolide resistance-associated mutations in C.
trachomatis clinical isolates obtained after ineffective therapy of
urogenital chlamydiasis with fluoroquinolones and macrolides
(Shkarupeta et al., 2007).
It is typical for chlamydia to acquire so-called heterotypic
resistance, a form of phenotypic resistance in which a small
proportion of an infecting microbial species is capable of
expressing resistance at any one time. Strains isolated from
patients after the failure of treatment with antimicrobial drugs are
fully sensitive to the same drugs in vitro, and only a small fraction
of the chlamydia population (<1%) survives in the presence of
high concentrations of the drugs (Shkarupeta et al., 2007).
Mycoplasna and Ureaplasma spp.
Because members of the genera Mycoplasma and Ureaplasma
have no cell wall, they are insensitive to all types of β-lactam
antibiotics (natural susceptibility). Sulfonamide at physiological
concentrations also has no effect on these bacteria due to the
absence of the metabolic pathway for the synthesis of folic
acid. High rates of resistance to erythromycin and tetracycline
in clinical specimens (from 73 to 97%) were reported for
Ureaplasma species and M. hominis. Speciation indicated that
U. parvum was the predominant Ureaplasma spp. that conferred
antimicrobial resistance. Specimens resistant to macrolides were
found, and cases of clinical and microbiological treatment failure
with moxifloxacin were also reported (Redelinghuys et al., 2014).
An increase in fluoroquinolone-resistantM. genitalium strains in
Japan has been recently reported, and the prevalence ofmacrolide
and fluoroquinolone resistance-associated mutations in DNA
specimens from men with non-gonococcal urethritis has been
determined (Kikuchi et al., 2014).
The resistance of Mycoplasma and Ureaplasma to antibiotics
is primarily associated with mutations in the 23S rRNA
(macrolides), gyrA, gyrB, parC, or parE gene (fluoroquinolones)
(Table 1). The mutations responsible for macrolide, lincosamide,
streptogramin, or ketolide group resistance occur in 23S rRNA
at positions 2610, 2611, 2057, 2059, and 2062 in M. hominis
(Escherichia coli numbering) and positions 2058 and 2059 in M.
genitalium. Deletions and insertions in the L4 ribosomal proteins
and mutations in the 23S rRNA at positions 2056, 2057, and
2058 are associated with macrolide resistance in Ureaplasma
spp. (Couldwell et al., 2013; Salado-Rasmussen and Jensen, 2014;
Waites and Xiao, 2015). The eﬄux genes and erm gene that
contribute to the resistance of Ureaplasma to macrolides have
been detected in only one work (Lu et al., 2010) and have not
been confirmed by other investigators.
Susceptibility of the M. hominis and Ureaplasma spp. to
tetracyclines was studied in South Africa (Redelinghuys et al.,
2014). The high-level resistance to tetracyclines in M. hominis
and Ureaplasma spp. is explained by the presence of the tet(M)
determinant that provides ribosome protection and represents
the sole tetracycline resistance mechanism acquired by clinical
isolates of human mycoplasmas (Dégrange et al., 2008). For M.
genitalium, treatment failures with tetracycline were reported but
no genes responsible for the resistance were identified (Waites
and Xiao, 2015).
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TABLE 1 | Molecular determinants of drug resistance and phenotypic susceptibility in Mycoplasmas and Ureaplasmas.
Antimicrobial drug Determinants of drug resistance Range of minimal inhibitory
concentrations for resistant isolates
(mg/L)
M. genitalium
Macrolides, lincosamides, streptogramins, ketolides Mutations in the 23S rRNA gene at positions 2058 and
2059*
16–64 for erythromycin
Mutations in L4 ribosomal protein
Tetracyclines No determinants have been detected for isolates
obtained in cases of treatment failures
No data available
Fluoroquinolones Mutations in the gyrA, gyrB, parC, or parE genes No data available
M. hominis
Macrolides, lincosamides, streptogramins, ketolides Mutations in the 23S rRNA gene at positions 2610,
2611, 2057, 2059, and 2062*
16–64 for clindamycin
Tetracyclines tet(M) determinant (ribosomal protection) 8–64 for tetracyclines
Fluoroquinolones Mutations in the gyrA, gyrB, parC, or parE genes 2–32 for levofloxacin
4–8 for ciprofloxacin
U. urealyticum and U. parvum
Macrolides, lincosamides, streptogramins, ketolides Deletions or insertions in L4 ribosomal proteins and/or
mutations in the 23S rRNA gene at position 2056, 2057,
and 2058
64–128 for erythromycin
Ribosomal methylation mediated by the ermB gene
mrsA/mrsB/mrsD efflux pumps
Tetracyclines tet(M) determinant (ribosomal protection) 2–32 for tetracyclines
Fluoroquinolones Mutations in the gyrA, gyrB, parC, or parE genes 2–16 for levofloxacin
*Escherichia coli numbering system.
DRUG RESISTANCE OF BV ASSOCIATED
BACTERIA
G. vaginalis
G. vaginalis is treated with metronidazole and clindamycin but
only limited data are available with respect to its resistance
(Nagaraja, 2008; Tomusiak et al., 2011). The putative mechanism
for tetracycline resistance is the presence of the tetM gene, which
is found in tetracycline-resistant strains of G. vaginalis (Harwich
et al., 2010). Resistance to metronidazole has been found in
someG. vaginalis strains. The proposedmechanisms of resistance
include (Löfmark et al., 2010):
- A suppressed rate of activation of the drug inside the cell
through its reduction;
- Increased activity of DNA repair systems;
- Increased activity of enzymes that consume oxygen (i.e.,
catalase, peroxidase, and superoxide reductase);
- Accelerated clearance of the drug from the cell by active eﬄux.
The most well-characterized mechanism of resistance to
metronidazole is the inactivation or deletion of genes with
nitroreductase activity (Dhand and Snydman, 2009). Some
isolates have nitroreductase genes; however, the correlation
between these genes and metronidazole resistance has not
been studied.
Recent whole-genome sequencing studies have revealed that
G. vaginalis has a population structure that consists of four clades:
clades 1 and 3 are associated with bacterial vaginosis and clades 2
and 4 are not. Metronidazole susceptibility is associated with the
population structure, with clade 3 and 4 isolates showing 100%
resistance to this drug whereas the resistance of clade 1 and 2 are
35 and 7.1%, respectively (Schuyler et al., 2015b).
B. fragilis
Recently, an increasing resistance to different antimicrobial
drugs has been reported for B. fragilis. Resistant strains were
discovered in both European countries and the United States.
(Eitel et al., 2013). Multidrug-resistant B. fragilis isolates bearing
parallel resistance to imipenem, amoxicillin and metronidazole
or clindamycin were also found in Russia (Shilnikova and
Dmitrieva, 2015). Antibiotic resistance is spread horizontally
among the B. fragilis group of clinical isolates due to the antibiotic
resistance genes carried on conjugative andmobilizable plasmids,
conjugative transposons and integrated genetic elements (Eitel
et al., 2013).
The most important mechanism of resistance of B. fragilis to
β-lactam antibiotics is the production of β-lactamases (Edwards,
1997). The cepA gene encodes β-lactamase, which is able to
destroy penicillins and most cephalosporins (except cefoxitin).
Resistance to cefoxitin-resistant strains was explained by the
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presence of the cfxA gene located on the MTn4555 transposon.
Resistance to carbapenems was explained by the presence of the
cfiA gene in the bacterial chromosome. Because the cfiA genemay
be expressed differently or even be silenced, different levels of
carbapenem resistance may be detected. As recently shown (Eitel
et al., 2013), the cfxA gene is not a major factor in determining
cefoxitin resistance, cfxA was found with a higher prevalence in
non-fragilis Bacteroides strains than in B. fragilis.
Metronidazole remains the drug of choice for the treatment of
infections caused by B. fragilis, although metronidazole-resistant
strains have been described in the literature (Brook, 2004). The
resistance is due to the presence of the nitroimidazole resistance
genes nimA-nimG on plasmids or on chromosomes (Carlier et al.,
1997).
B. fragilis resistance to tetracycline originates from the
presence of the tetQ gene (ribosome protection mechanism)
and the tetX and tetX1 genes encoding FAD-dependent
monooxygenases that are able to destroy tetracycline.
B. fragilis resistance to clindamycin occurs via two
mechanisms. First, the ermB, ermF, and ermG genes encoding
various N6-methyltransferases modify the 23S RNA. Several
transferable plasmids can cause resistance [pBF4, pBFTM10
(pCP1), and pB1136]. The ermF resistance gene was found
on transposons Tn4351 (pBF4), Tn4400 (pBFTM10), and
Tn4551 (pB1136). Among the possible clindamycin resistance
genes, ermF was the most common and had the largest effect
on clindamycin resistance after the linA gene. The second
mechanism is the action of the eﬄux pumps encoded by the
msrSA and mefA genes. The msrSA gene was first described for
Staphylococcus aureus and was later also found in Bacteroides.
The presence of the ermG-mefA-msrSA combination was
confirmed for clindamycin-resistant B. fragilis strains (Eitel et al.,
2013).
Members of the Bacteroides genus were originally resistant to
first and second generation fluoroquinolones. Resistance to the
next generation fluoroquinolones appeared in the last few years;
however, fluoroquinolones of the third and fourth generations
are still effective against B. fragilis. The BexA eﬄux pump
encoded by the bexA gene may be responsible for the resistance
of B. fragilis to fluoroquinolones and the elevated moxifloxacin
MIC values. The BexA pump belongs to the MATE class. It
was first described for Bacteroides thetaiotaomicron; disruption of
BexA in B. thetaiotaomicron made the bacteria more susceptible
to norfloxacin, ciprofloxacin, and ethidium bromide. The BexA
protein sequence is homologous to the protein sequence of
NorM, which is a multidrug eﬄux transporter of Vibrio
parahaemolyticus (Miyamae et al., 2001).
A. vaginae
Some studies demonstrated that A. vaginae could exhibit a
high level of resistance to metronidazole (Geißdörfer et al.,
2003). For example, several isolates of A. vaginae described in
De Backer et al. (2006) were found to be highly resistant to
metronidazole and susceptible to clindamycin, which are the
two preferred antibiotics for the treatment of bacterial vaginosis;
however, a large amount of variability in the susceptibility to
metronidazole was reported (ranging from 2 to more than
256mg/L). The authors concluded that metronidazole resistance
was not an intrinsic feature of A. vaginae. Further research is
required to clarify whether this metronidazole resistance might
be acquired by the presence and activation of nim-genes encoding
an alternative reductase that can convert nitroimidazole to a
nontoxic derivative, thereby circumventing the toxic effect that
causes breakage of the DNA (Löfmark et al., 2010).
A draft genome sequence of a metronidazole-susceptible
(MIC 16 mg/L) vaginal isolate of A. vaginae (strain 44061) was
recently published (Schuyler et al., 2015a). This information will
be useful for comparative studies of the mechanism and the
molecular basis of metronidazole resistance in A. vaginae.
M. mulieris
In different studies, the resistance ofM.mulieris tometronidazole
varied from 50 to 81%. The MIC90 of metronidazole was 128
mg/L. Reports have suggested that 4% of Mobiluncus species are
clindamycin-resistant (Spiegel, 1987; Bahar et al., 2005). A high
prevalence of metronidazole-resistant Mobiluncus species (81%)
was found among Turkish women with gynecological infections
including bacterial vaginosis (Bahar et al., 2005). Notably, the
tetQ gene that was associated with resistance to tetracycline was
found inMobiluncus.
CONCLUSION
The emergence of resistance to antimicrobials is a natural
consequence of the evolutionary process under increasing
pressure from chemotherapy. As a result, resistance of STD
pathogens appears to not only natural β-lactam antibiotics,
but also to fully synthetic drugs such as fluoroquinolones.
In the ongoing war between the disease and its effective
treatment, a detailed understanding of the mechanisms of action
of antibiotics and the emergence of resistance is necessary
to modify existing drugs and to develop new ones directed
against new targets. An ever-increasing range of reproductive
tract bacterial infections calls for developing rapid, sensitive,
and reliable methods that are able to determine resistance
to available antimicrobials in individual patients as early as
possible. At the same time, the recommended therapeutic
regimen should take into account the regional occurrence of
resistance to specific drugs obtained by constant monitoring.
Moreover, for adequate therapy of diseases of the urogenital
tract, in particular, for targeted selection of drugs, it is very
important to take into account the possible polymicrobial
character of a disease and to be able to simultaneously identify
several STD pathogens and BV associated bacteria in individual
clinical samples. These strategies will allow the use of existing
drugs for a longer time with better efficiency and suppress the
occurrence of multidrug-resistant bacterial microflora generated
by repetitive failures of treatment with already inefficient
antibiotics.
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